<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35846757</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2235-2988</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in cellular and infection microbiology</Title><ISOAbbreviation>Front Cell Infect Microbiol</ISOAbbreviation></Journal><ArticleTitle>Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome.</ArticleTitle><Pagination><StartPage>922422</StartPage><MedlinePgn>922422</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">922422</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcimb.2022.922422</ELocationID><Abstract><AbstractText>The duration and severity of COVID-19 are related to age, comorbidities, and cytokine synthesis. This study evaluated the impact of these factors on patients with clinical presentations of COVID-19 in a Brazilian cohort. A total of 317 patients diagnosed with COVID-19 were included; cases were distributed according to clinical status as severe (n=91), moderate (n=56) and mild (n=170). Of these patients, 92 had acute COVID-19 at sample collection, 90 had already recovered from COVID-19 without sequelae, and 135 had sequelae (long COVID syndrome). In the acute COVID-19 group, patients with the severe form had higher IL-6 levels (p=0.0260). In the post-COVID-19 group, there was no significant difference in cytokine levels between groups with different clinical conditions. In the acute COVID-19 group, younger patients had higher levels of TNF-&#x3b1;, and patients without comorbidities had higher levels of TNF-&#x3b1;, IL-4 and IL-2 (p&lt;0.05). In contrast, patients over age 60 with comorbidities had higher levels of IL-6. In the post-COVID-19 group, subjects with long COVID-19 had higher levels of IL-17 and IL-2 (p&lt;0.05), and subjects without sequelae had higher levels of IL-10, IL-6 and IL- 4 (p&lt;0.05). Our results suggest that advanced age, comorbidities and elevated serum IL-6 levels are associated with severe COVID-19 and are good markers to differentiate severe from mild cases. Furthermore, high serum levels of IL-17 and IL-2 and low levels of IL-4 and IL-10 appear to constitute a cytokine profile of long COVID-19, and these markers are potential targets for COVID-19 treatment and prevention strategies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Queiroz, Neves, Lima, Lopes, Torres, Vallinoto, Bichara, Santos, de Brito, da Silva, Leite, da Costa, Viana, Rodrigues, de Sarges, Cantanhede, da Silva, Bichara, Berg, Ver&#xed;ssimo, Carvalho, Henriques, Santos, Nunes, Costa, Viana, Carneiro, Palacios, Quaresma, Brasil-Costa, Santos, Falc&#xe3;o and Vallinoto.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Queiroz</LastName><ForeName>Maria Alice Freitas</ForeName><Initials>MAF</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neves</LastName><ForeName>Pablo Fabiano Moura das</ForeName><Initials>PFMD</Initials><AffiliationInfo><Affiliation>Instituto de Ci&#xea;ncias Biol&#xf3;gicas e da Sa&#xfa;de, Universidade do Estado do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Sandra Souza</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Jeferson da Costa</ForeName><Initials>JDC</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Maria Karoliny da Silva</ForeName><Initials>MKDS</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallinoto</LastName><ForeName>Izaura Maria Vieira Cayres</ForeName><Initials>IMVC</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bichara</LastName><ForeName>Carlos David Ara&#xfa;jo</ForeName><Initials>CDA</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Santos</LastName><ForeName>Erika Ferreira</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Brito</LastName><ForeName>Mioni Thieli Figueiredo Magalh&#xe3;es</ForeName><Initials>MTFM</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Andr&#xe9;a Luciana Soares</ForeName><Initials>ALS</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leite</LastName><ForeName>Mauro de Meira</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Costa</LastName><ForeName>Fl&#xe1;via P&#xf3;voa</ForeName><Initials>FP</Initials><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viana</LastName><ForeName>Maria de Nazar&#xe9; do Socorro de Almeida</ForeName><Initials>MNDSA</Initials><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigues</LastName><ForeName>Fab&#xed;ola Brasil Barbosa</ForeName><Initials>FBB</Initials><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Sarges</LastName><ForeName>Kevin Matheus Lima</ForeName><Initials>KML</Initials><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantanhede</LastName><ForeName>Marcos Henrique Damasceno</ForeName><Initials>MHD</Initials><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva</LastName><ForeName>Rosilene</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Gen&#xe9;tica de Doen&#xe7;as Complexas, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bichara</LastName><ForeName>Clea Nazar&#xe9; Carneiro</ForeName><Initials>CNC</Initials><AffiliationInfo><Affiliation>Instituto de Ci&#xea;ncias Biol&#xf3;gicas e da Sa&#xfa;de, Universidade do Estado do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Ana Virg&#xed;nia Soares</ForeName><Initials>AVS</Initials><AffiliationInfo><Affiliation>Instituto de Ci&#xea;ncias Biol&#xf3;gicas e da Sa&#xfa;de, Universidade do Estado do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ver&#xed;ssimo</LastName><ForeName>Adriana de Oliveira Lameira</ForeName><Initials>AOL</Initials><AffiliationInfo><Affiliation>Hospital Adventista de Bel&#xe9;m, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>Mayara da Silva</ForeName><Initials>MDS</Initials><AffiliationInfo><Affiliation>Hospital Adventista de Bel&#xe9;m, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriques</LastName><ForeName>Daniele Freitas</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Se&#xe7;&#xe3;o de Arbovirologia e Febres Hemorr&#xe1;gicas, Instituto Evandro Chagas, Secret&#xe1;ria de Vigil&#xe2;ncia em Sa&#xfa;de, Minist&#xe9;rio da Sa&#xfa;de do Brasil, Ananindeua, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Santos</LastName><ForeName>Carla Pinheiro</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Se&#xe7;&#xe3;o de Arbovirologia e Febres Hemorr&#xe1;gicas, Instituto Evandro Chagas, Secret&#xe1;ria de Vigil&#xe2;ncia em Sa&#xfa;de, Minist&#xe9;rio da Sa&#xfa;de do Brasil, Ananindeua, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunes</LastName><ForeName>Juliana Abreu Lima</ForeName><Initials>JAL</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Imunologia, Se&#xe7;&#xe3;o de Virologia, Instituto Evandro Chagas, Secret&#xe1;ria de Vigil&#xe2;ncia em Sa&#xfa;de, Minist&#xe9;rio da Sa&#xfa;de do Brasil, Ananindeua, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Iran Barros</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Imunologia, Se&#xe7;&#xe3;o de Virologia, Instituto Evandro Chagas, Secret&#xe1;ria de Vigil&#xe2;ncia em Sa&#xfa;de, Minist&#xe9;rio da Sa&#xfa;de do Brasil, Ananindeua, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viana</LastName><ForeName>Giselle Maria Rachid</ForeName><Initials>GMR</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Pesquisas B&#xe1;sicas em Mal&#xe1;ria em Mal&#xe1;ria, Se&#xe7;&#xe3;o de Parasitologia, Instituto Evandro Chagas, Secret&#xe1;ria de Vigil&#xe2;ncia em Sa&#xfa;de, Minist&#xe9;rio da Sa&#xfa;de do Brasil, Ananindeua, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carneiro</LastName><ForeName>Francisca Regina Oliveira</ForeName><Initials>FRO</Initials><AffiliationInfo><Affiliation>Instituto de Ci&#xea;ncias Biol&#xf3;gicas e da Sa&#xfa;de, Universidade do Estado do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palacios</LastName><ForeName>Vera Regina da Cunha Menezes</ForeName><Initials>VRDCM</Initials><AffiliationInfo><Affiliation>Instituto de Ci&#xea;ncias Biol&#xf3;gicas e da Sa&#xfa;de, Universidade do Estado do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quaresma</LastName><ForeName>Juarez Antonio Sim&#xf5;es</ForeName><Initials>JAS</Initials><AffiliationInfo><Affiliation>Instituto de Ci&#xea;ncias Biol&#xf3;gicas e da Sa&#xfa;de, Universidade do Estado do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brasil-Costa</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Imunologia, Se&#xe7;&#xe3;o de Virologia, Instituto Evandro Chagas, Secret&#xe1;ria de Vigil&#xe2;ncia em Sa&#xfa;de, Minist&#xe9;rio da Sa&#xfa;de do Brasil, Ananindeua, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Santos</LastName><ForeName>Eduardo Jos&#xe9; Melo</ForeName><Initials>EJM</Initials><AffiliationInfo><Affiliation>Programa de P&#xf3;s-Gradua&#xe7;&#xe3;o em Biologia de Agentes Infecciosos e Parasit&#xe1;rios, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falc&#xe3;o</LastName><ForeName>Luiz F&#xe1;bio Magno</ForeName><Initials>LFM</Initials><AffiliationInfo><Affiliation>Instituto de Ci&#xea;ncias Biol&#xf3;gicas e da Sa&#xfa;de, Universidade do Estado do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallinoto</LastName><ForeName>Antonio Carlos Ros&#xe1;rio</ForeName><Initials>ACR</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Virologia, Instituto de Ci&#xea;ncias Biol&#xf3;gicas, Universidade Federal do Par&#xe1;, Bel&#xe9;m, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Infect Microbiol</MedlineTA><NlmUniqueID>101585359</NlmUniqueID><ISSNLinking>2235-2988</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>18</Day><Hour>4</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35846757</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Post-COVID-19 syndrome: in it for the long haul. (2021). EBioMedicine 67, 103424. doi:&#xa0;10.1016/j.ebiom.2021.103424</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103424</ArticleId><ArticleId IdType="pmc">PMC8153191</ArticleId><ArticleId IdType="pubmed">34051888</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdallah S. J., Voduc N., Corrales-Medina V. F., McGuinty M., Pratt A., Chopra A., et al. . (2021). Symptoms, Pulmonary Function, and Functional Capacity Four Months After COVID-19. Ann. Am. Thorac. Soc 18, 1912&#x2013;1917. doi:&#xa0;10.1513/AnnalsATS.202012-1489RL</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202012-1489RL</ArticleId><ArticleId IdType="pmc">PMC8641826</ArticleId><ArticleId IdType="pubmed">33872135</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M., Schommers P., Stecher M., Dewald F., Gieselmann L., Gruell H., et al. . (2021). Post-COVID Syndrome in non-Hospitalised Patients With COVID-19: A Longitudinal Prospective Cohort Study. Lancet Reg. Health Eur. 6, 100122. doi:&#xa0;10.1016/j.lanepe.2021.100122</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi L., Mescia F., Turner L., Hanson A. L., Kotagiri P., Dunmore B. J., et al. . (2021). Longitudinal Analysis Reveals That Delayed Bystander CD8+ T Cell Activation and Early Immune Pathology Distinguish Severe COVID-19 From Mild Disease. Immunity 54, 1257&#x2013;1275. doi:&#xa0;10.1016/j.immuni.2021.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8125900</ArticleId><ArticleId IdType="pubmed">34051148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bichara C. D. A., da Silva Gra&#xe7;a Amoras E., Vaz G. L., da Silva Torres M. K., Queiroz M. A. F., do Amaral I. P. C., et al. . (2021. b). Dynamics of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 in a Brazilian Amazon Population. BMC Infect. Dis. 21, 443. doi:&#xa0;10.1186/s12879-021-06156-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06156-x</ArticleId><ArticleId IdType="pmc">PMC8122196</ArticleId><ArticleId IdType="pubmed">33992073</ArticleId></ArticleIdList></Reference><Reference><Citation>Bichara C. D. A., Queiroz M. A. F., da Silva Gra&#xe7;a Amoras E., Vaz G. L., Vallinoto I. M. V. C., Bichara C. N. C., et al. . (2021. a). Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil. Vaccines (Basel) 9, 1169. doi:&#xa0;10.3390/vaccines9101169</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9101169</ArticleId><ArticleId IdType="pmc">PMC8539673</ArticleId><ArticleId IdType="pubmed">34696277</ArticleId></ArticleIdList></Reference><Reference><Citation>Buszko M., Park J. H., Verthelyi D., Sen R., Young H. A., Rosenberg A. S. (2020). The Dynamic Changes in Cytokine Responses in COVID-19: A Snapshot of the Current State of Knowledge. Nat. Immunol. 21, 1146&#x2013;1151. doi:&#xa0;10.1038/s41590-020-0779-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0779-1</ArticleId><ArticleId IdType="pubmed">32855555</ArticleId></ArticleIdList></Reference><Reference><Citation>Camargo-Mart&#xed;nez W., Lozada-Mart&#xed;nez I., Escobar-Collazos A., Navarro-Coronado A., Moscote-Salazar L., Pacheco-Hern&#xe1;ndez A., et al. . (2021). Post-COVID 19 Neurological Syndrome: Implications for Sequelae's Treatment. J. Clin. Neurosci. 88, 219&#x2013;225. doi:&#xa0;10.1016/j.jocn.2021.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2021.04.001</ArticleId><ArticleId IdType="pmc">PMC8031003</ArticleId><ArticleId IdType="pubmed">33992187</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC COVID-19 Response Team . (2020). Severe Outcomes Among Patients With Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb. Mortal. Wkly. Rep. 69, 343&#x2013;346. doi:&#xa0;10.15585/mmwr.mm6912e2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6912e2</ArticleId><ArticleId IdType="pmc">PMC7725513</ArticleId><ArticleId IdType="pubmed">32214079</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S. H., Minn D., Kim S. W., Kim Y. K. (2021). Inflammatory Markers and Cytokines in Moderate and Critical Cases of COVID-19. Clin. Lab. 67 (9). doi:&#xa0;10.7754/Clin.Lab.2021.210142</Citation><ArticleIdList><ArticleId IdType="doi">10.7754/Clin.Lab.2021.210142</ArticleId><ArticleId IdType="pubmed">34542974</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Klein S. L., Garibaldi B. T., Li H., Wu C., Osevala N. M., et al. . (2021). Aging in COVID-19: Vulnerability, Immunity and Intervention. Ageing Res. Rev. 65, 101205. doi:&#xa0;10.1016/j.arr.2020.101205</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2020.101205</ArticleId><ArticleId IdType="pmc">PMC7604159</ArticleId><ArticleId IdType="pubmed">33137510</ArticleId></ArticleIdList></Reference><Reference><Citation>
Collins F. S. (2021) NIH Launches New Initiative to Study &#x201c;Long COVID&#x201d; (Bethesda, MD, USA: National Institutes of Health; ). Available at: https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covid (Accessed 27/05/2022).</Citation></Reference><Reference><Citation>Darley D. R., Dore G. J., Byrne A. L., Plit M. L., Brew B. J., Kelleher A., et al. . (2021). Limited Recovery From Post-Acute Sequelae of SARS-CoV-2 at 8 Months in a Prospective Cohort. ERJ Open Res. 7, 00384&#x2013;02021. doi:&#xa0;10.1183/23120541.00384-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00384-2021</ArticleId><ArticleId IdType="pmc">PMC8504133</ArticleId><ArticleId IdType="pubmed">34725634</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle D. M., Kim-Schulze S., Huang H. H., Beckmann N. D., Nirenberg S., Wang B., et al. . (2020). An Inflammatory Cytokine Signature Predicts COVID-19 Severity and Survival. Nat. Med. 6, 1636&#x2013;1643. doi:&#xa0;10.1038/s41591-020-1051-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Donath M. Y., Dinarello C. A., Mandrup-Poulsen T. (2019). Targeting Innate Immune Mediators in Type 1 and Type 2 Diabetes. Nat. Rev. Immunol. 19, 734&#x2013;746. doi:&#xa0;10.1038/s41577-019-0213-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0213-9</ArticleId><ArticleId IdType="pubmed">31501536</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejaz H., Alsrhani A., Zafar A., Javed H., Junaid K., Abdalla A. E., et al. . (2020). COVID-19 and Comorbidities: Deleterious Impact on Infected Patients. J. Infect. Public Health 13, 1833&#x2013;1839. doi:&#xa0;10.1016/j.jiph.2020.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.07.014</ArticleId><ArticleId IdType="pmc">PMC7402107</ArticleId><ArticleId IdType="pubmed">32788073</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Kadre L. J., Tinoco A. C. (2013). Interleukin-6 and Obesity: The Crosstalk Between Intestine, Pancreas and Liver. Curr. Opin. Clin. Nutr. Metab. Care 16, 564&#x2013;568. doi:&#xa0;10.1097/MCO.0b013e32836410e6</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCO.0b013e32836410e6</ArticleId><ArticleId IdType="pubmed">23924949</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X., Li S., Yu H., Wang P., Zhang Y., Chen Z., et al. . (2020). Epidemiological, Comorbidity Factors With Severity and Prognosis of COVID-19: A Systematic Review and Meta-Analysis. Aging (Albany NY) 12, 12493&#x2013;12503. doi:&#xa0;10.18632/aging.103579</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103579</ArticleId><ArticleId IdType="pmc">PMC7377860</ArticleId><ArticleId IdType="pubmed">32658868</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Palacios-Ce&#xf1;a D., G&#xf3;mez-Mayordomo V., Rodr&#xed;uez-Jim&#xe9;nez J., Palacios-Ce&#xf1;a M., Velasco-Arribas M., et al. . (2021). Long-Term Post-COVID Symptoms and Associated Risk Factors in Previously Hospitalized Patients: A Multicenter Study. J. Infect. 83, 237&#x2013;279. doi:&#xa0;10.1016/j.jinf.2021.04.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.04.036</ArticleId><ArticleId IdType="pmc">PMC8110627</ArticleId><ArticleId IdType="pubmed">33984399</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschi C., Campisi J. (2014). Chronic Inflammation (Inflammaging) and its Potential Contribution to Age-Associated Diseases. J. Gerontol A Biol. Sci. Med. Sci. 69, S4&#x2013;S9. doi:&#xa0;10.1093/gerona/glu057</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glu057</ArticleId><ArticleId IdType="pubmed">24833586</ArticleId></ArticleIdList></Reference><Reference><Citation>Freire P. P., Marques A. H., Baiocchi G. C., Schimke L. F., Fonseca D. L., Salgado R. C., et al. . (2021). The Relationship Between Cytokine and Neutrophil Gene Network Distinguishes SARS-CoV-2-Infected Patients by Sex and Age. JCI Insight 6, e147535. doi:&#xa0;10.1172/jci.insight.147535</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.147535</ArticleId><ArticleId IdType="pmc">PMC8262322</ArticleId><ArticleId IdType="pubmed">34027897</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerlings S. E., Hoepelman A. I. (1999). Immune Dysfunction in Patients With Diabetes Mellitus (DM). FEMS Immunol. Med. Microbiol. 26, 259&#x2013;265. doi:&#xa0;10.1111/j.1574-695X.1999.tb01397.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-695X.1999.tb01397.x</ArticleId><ArticleId IdType="pubmed">10575137</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J., Tacquard C., Severac F., Leonard-Lorant I., Ohana M., Delabranche X., et al. . (2020). High Risk of Thrombosis in Patients With Severe SARS-CoV-2 Infection: A Multicenter Prospective Cohort Study. Intensive Care Med. 46, 1089&#x2013;1098. doi:&#xa0;10.1007/s00134-020-06062-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06062-x</ArticleId><ArticleId IdType="pmc">PMC7197634</ArticleId><ArticleId IdType="pubmed">32367170</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., et al. . (2021. b). 6-Month Consequences of COVID-19 in Patients Discharged From Hospital: A Cohort Study. Lancet 397, 220&#x2013;232. doi:&#xa0;10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. . (2021. a). Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan, China. Lancet 395, 497&#x2013;506. doi:&#xa0;10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappelmann N., Dantzer R., Khandaker G. M. (2021). Interleukin-6 as Potential Mediator of Long-Term Neuropsychiatric Symptoms of COVID-19. Psychoneuroendocrinology 131, 105295. doi:&#xa0;10.1016/j.psyneuen.2021.105295</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2021.105295</ArticleId><ArticleId IdType="pmc">PMC8172271</ArticleId><ArticleId IdType="pubmed">34119855</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur S., Bansal R., Kollimuttathuillam S., Gowda A. M., Singh B., Mehta D., et al. . (2021). The Looming Storm: Blood and Cytokines in COVID-19. Blood Rev. 46, 100743. doi:&#xa0;10.1016/j.blre.2020.100743</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2020.100743</ArticleId><ArticleId IdType="pmc">PMC7431319</ArticleId><ArticleId IdType="pubmed">32829962</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F. A., Kruip M. J. H. A., van der Meer N. J. M., Arbous M. S., Gommers D. A. M. P. J., Kant K. M., et al. . (2020). Incidence of Thrombotic Complications in Critically Ill ICU Patients With COVID-19. Thromb. Res. 191, 145&#x2013;147. doi:&#xa0;10.1016/j.thromres.2020.04.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.04.013</ArticleId><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunnumakkara A. B., Rana V., Parama D., Banik K., Girisa S., Henamayee S., et al. . (2021). COVID-19, Cytokines, Inflammation, and Spices: How are They Related? Life Sci. 284, 119201. doi:&#xa0;10.1016/j.lfs.2021.119201</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.119201</ArticleId><ArticleId IdType="pmc">PMC7884924</ArticleId><ArticleId IdType="pubmed">33607159</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechner-Scott J., Levy M., Hawkes C., Yeh A., Giovannoni G. (2021). Long COVID or Post COVID-19 Syndrome. Mult. Scler. Relat. Disord. 55, 103268. doi:&#xa0;10.1016/j.msard.2021.103268</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2021.103268</ArticleId><ArticleId IdType="pmc">PMC8447548</ArticleId><ArticleId IdType="pubmed">34601388</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue J. K., Franko N. M., McCulloch D. J., McDonald D., Magedson A., Wolf C. R., et al. . (2021). Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw. Open 4, e210830. doi:&#xa0;10.1001/jamanetworkopen.2021.0830</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe G. D., Rumley A., McMahon A. D., Ford I., O'Reilly D. S., Packard C. J., et al. . (2004). Interleukin-6, Fibrin D-Dimer, and Coagulation Factors VII and XIIa in Prediction of Coronary Heart Disease. Arterioscler. Thromb. Vasc. Biol. 24, 1529&#x2013;1534. doi:&#xa0;10.1161/01.ATV.0000135995.39488.6c</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000135995.39488.6c</ArticleId><ArticleId IdType="pubmed">15205218</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggio M., Guralnik J. M., Longo D. L., Ferrucci L. (2006). Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway. J. Gerontol A Biol. Sci. Med. Sci. 61, 575&#x2013;584. doi:&#xa0;10.1093/gerona/61.6.575</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/61.6.575</ArticleId><ArticleId IdType="pmc">PMC2645627</ArticleId><ArticleId IdType="pubmed">16799139</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin V., Montero-Julian F. A., Gr&#xe8;s S., Boulay V., Bongrand P., Farnarier C., et al. . (2001). The IL-6-Soluble IL-6Ralpha Autocrine Loop of Endothelial Activation as an Intermediate Between Acute and Chronic Inflammation: An Experimental Model Involving Thrombin. J. Immunol. 167, 3435&#x2013;4342. doi:&#xa0;10.4049/jimmunol.167.6.3435</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.167.6.3435</ArticleId><ArticleId IdType="pubmed">11544336</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirhafez S. R., Mohebati M., Feiz Disfani M., Saberi Karimian M., Ebrahimi M., Avan A., et al. . (2014). An Imbalance in Serum Concentrations of Inflammatory and Anti-Inflammatory Cytokines in Hypertension. J. Am. Soc. Hypertens. 8, 614&#x2013;623. doi:&#xa0;10.1016/j.jash.2014.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jash.2014.05.007</ArticleId><ArticleId IdType="pubmed">25224864</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghbeli M., Khedmatgozar H., Yadegari M., Avan A., Ferns G. A., Ghayour Mobarhan M. (2021). Cytokines and the Immune Response in Obesity-Related Disorders. Adv. Clin. Chem. 101, 135&#x2013;168. doi:&#xa0;10.1016/bs.acc.2020.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.acc.2020.06.004</ArticleId><ArticleId IdType="pubmed">33706888</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-P&#xe9;rez O., Merino E., Leon-Ramirez J. M., Andres M., Ramos J. M., Arenas-Jim&#xe9;nez J., et al. . (2021). Post-Acute COVID-19 Syndrome. Incidence and Risk Factors: A Mediterranean Cohort Study. J. Infect. 82, 378&#x2013;383. doi:&#xa0;10.1016/j.jinf.2021.01.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortaz E., Tabarsi P., Varahram M., Folkerts G., Adcock I. M. (2020). The Immune Response and Immunopathology of COVID-19. Front. Immunol. 11. doi:&#xa0;10.3389/fimmu.2020.02037</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.02037</ArticleId><ArticleId IdType="pmc">PMC7479965</ArticleId><ArticleId IdType="pubmed">32983152</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy &#xc1;., Pongor S., Gy&#x151;rffy B. (2021). Different Mutations in SARS-CoV-2 Associate With Severe and Mild Outcome. Int. J. Antimicrob. Agents 57, 106272. doi:&#xa0;10.1016/j.ijantimicag.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020</ArticleId><ArticleId IdType="pmc">PMC7755579</ArticleId><ArticleId IdType="pubmed">33347989</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums D. V. (2021). Editorial: Long COVID, or Post-COVID Syndrome, and the Global Impact on Health Care. Med. Sci. Monit. 27, e933446. doi:&#xa0;10.12659/MSM.933446</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.933446</ArticleId><ArticleId IdType="pmc">PMC8194290</ArticleId><ArticleId IdType="pubmed">34092779</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawelec G. (2018). Age and Immunity: What Is &#x201c;Immunosenescence&#x201d;? Exp. Gerontol. 105, 4&#x2013;9. doi:&#xa0;10.1016/j.exger.2017.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2017.10.024</ArticleId><ArticleId IdType="pubmed">29111233</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedemann N. C., Neff T. A., Guo R. F., Bernacki K. D., Laudes I. J., Sarma J. V., et al. . (2003). Protective Effects of IL-6 Blockade in Sepsis are Linked to Reduced C5a Receptor Expression. J. Immunol. 170, 503&#x2013;507. doi:&#xa0;10.4049/jimmunol.170.1.503</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.1.503</ArticleId><ArticleId IdType="pubmed">12496437</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha V. Z., Folco E. J. (2011). Inflammatory Concepts of Obesity. Int. J. Inflam. 2011, 529061. doi:&#xa0;10.4061/2011/529061</Citation><ArticleIdList><ArticleId IdType="doi">10.4061/2011/529061</ArticleId><ArticleId IdType="pmc">PMC3151511</ArticleId><ArticleId IdType="pubmed">21837268</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Iturbe B., Pons H., Quiroz Y., Johnson R. J. (2014). The Immunological Basis of Hypertension. Am. J. Hypertens. 27, 1327&#x2013;1337. doi:&#xa0;10.1093/ajh/hpu142</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajh/hpu142</ArticleId><ArticleId IdType="pmc">PMC4263946</ArticleId><ArticleId IdType="pubmed">25150828</ArticleId></ArticleIdList></Reference><Reference><Citation>Schimke L. F., Marques A. H. C., Baiocchi G. C., de Souza Prado C. A., Fonseca D. L. M., et al. . (2022). Severe COVID-19 Shares a Common Neutrophil Activation Signature With Other Acute Inflammatory States. Cells 11, 847. doi:&#xa0;10.3390/cells11050847</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11050847</ArticleId><ArticleId IdType="pmc">PMC8909161</ArticleId><ArticleId IdType="pubmed">35269470</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuwa H. A., Shaw T. N., Knight S. B., Wemyss K., McClure F. A., Pearmain L., et al. . (2021). Alterations in T and B Cell Function Persist in Convalescent COVID-19 Patients. Med. (N Y) 2, 720&#x2013;735.e4. doi:&#xa0;10.1016/j.medj.2021.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.03.013</ArticleId><ArticleId IdType="pmc">PMC8011689</ArticleId><ArticleId IdType="pubmed">33821250</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo P. A., Dogra P., Gray J. I., Wells S. B., Connors T. J., Weisberg S. P., et al. . (2021). Longitudinal Profiling of Respiratory and Systemic Immune Responses Reveals Myeloid Cell-Driven Lung Inflammation in Severe COVID-19. Immunity 54, 797&#x2013;814. doi:&#xa0;10.1016/j.immuni.2021.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.03.005</ArticleId><ArticleId IdType="pmc">PMC7951561</ArticleId><ArticleId IdType="pubmed">33765436</ArticleId></ArticleIdList></Reference><Reference><Citation>Teijaro J. R. (2017). Cytokine Storms in Infectious Diseases. Semin. Immunopathol. 39, 501&#x2013;503. doi:&#xa0;10.1007/s00281-017-0640-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0640-2</ArticleId><ArticleId IdType="pmc">PMC7079934</ArticleId><ArticleId IdType="pubmed">28674818</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres M. K. S., Bichara C. D. A., Almeida M. N. S., Vallinoto M. C., Queiroz M. A. F., Vallinoto I. M. V. C., et al. . (2022). The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic. Front. Microbiol. 13. doi:&#xa0;10.3389/fmicb.2022.789882</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.789882</ArticleId><ArticleId IdType="pmc">PMC8870622</ArticleId><ArticleId IdType="pubmed">35222327</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Cao J., Yu Y., Ding J., Eshak E. S., Liu K., et al. . (2020). Epidemiological Characteristics of Patients With Severe COVID-19 Infection in Wuhan, China: Evidence From a Retrospective Observational Study. Int. J. Epidemiol. 49, 1940&#x2013;1950. doi:&#xa0;10.1093/ije/dyaa180</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa180</ArticleId><ArticleId IdType="pmc">PMC7665537</ArticleId><ArticleId IdType="pubmed">33150437</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO  (2021) WHO Global Clinical Platform for the Clinical Characterization of COVID-19: Statistical Analysis Plan. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical-Analytic-plan-2021.1 (Accessed 15/02/2022).</Citation></Reference><Reference><Citation>
WHO  (2022) WHO Coronavirus (COVID-19) Dashboard. Available at: https://covid19.who.int/ (Accessed 08/02/2022).</Citation></Reference><Reference><Citation>Wool G. D., Miller J. L. (2021). The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology 88, 15&#x2013;27. doi:&#xa0;10.1159/000512007</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000512007</ArticleId><ArticleId IdType="pmc">PMC7649697</ArticleId><ArticleId IdType="pubmed">33049751</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L., Wu Y., Xiong H., Mei B., You T. (2021). Persistence of Symptoms After Discharge of Patients Hospitalized Due to COVID-19. Front. Med. (Lausanne) 8. doi:&#xa0;10.3389/fmed.2021.761314</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.761314</ArticleId><ArticleId IdType="pmc">PMC8645792</ArticleId><ArticleId IdType="pubmed">34881263</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. . (2020). Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet 395, 1054&#x2013;1062. doi:&#xa0;10.1016/S0140-6736(20)30566-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>